Targeted Medical Pharma Inc., of Los Angeles, said results from an open-label study of oral amino acid-based erythrocyte stimulating system (ESS) for the treatment of chronic anemia showed that hemoglobin increased an average of 11.39 percent from baseline measurement to 45 days...Vertex Pharmaceuticals Inc., of Cambridge, Mass., said VX-787 in a Phase II influenza challenge study resulted in statistically significant improvements in viral and clinical measurements of infection...Also, 93 percent of

Cerulean Pharma Inc., of Cambridge, Mass., said CRLX101 achieved the predefined gating criterion for advancement into the second stage of a Phase II trial in advanced ovarian cancer...Lorus Therapeutics Inc., of Toronto, said its Phase I study of LOR-253, a drug designed to target KLF4, successfully escalated to the target dose level based on predicted and observed clinical effects without limitation by toxicity...The complete clinical study report for the interim analysis would be supplied to the FDA

CicloMulsion is a cyclophilin inhibitor in clinical development to treat cardiac reperfusion injury and, under the name NeuroSTAT, in development for traumatic brain injury...Noxxon Pharma AG, of Berlin, said it treated the first patients in a Phase IIa trial of its anti-hepcidin Spiegelmer NOX-H94 to treat anemia associated with chronic disease...The vaccine was found to be safe at all dose levels, and the 108 PFU dose was selected for evaluation in a follow-on trial

The seven-day study evaluated the safety and efficacy of three dose levels of AR-13324, administered once daily in the morning...The clinical significance of those analyses is unknown. (See BioWorld Today, March 28, 2012...TransTech Pharma Inc., of High Point, N.C., said recruitment for its recently initiated Phase III trial with TTP054 in Type II diabetics is exceeding expectations with initial top-line results to be available in early 2013

The seven-day study evaluated the safety and efficacy of three dose levels of AR-13324, administered once daily in the morning...The clinical significance of those analyses is unknown. (See BioWorld Today, March 28, 2012...TransTech Pharma Inc., of High Point, N.C., said recruitment for its recently initiated Phase III trial with TTP054 in Type II diabetics is exceeding expectations with initial top-line results to be available in early 2013

The planned dose levels for the second, third and fourth groups are 0.05 mg/kg, 0.2 mg/kg and 0.375 mg/kg, respectively...Zealand Pharma A/S, of Copenhagen, Denmark, said it dosed the first patient in a Phase I study of ZP2929, a dual-acting glucagon/GLP-1 peptide agonist, in development for treating patients with Type II diabetes and/or patients with obesity

Proacta Inc., of San Diego, said the FDA cleared its investigational new drug application for clinical testing of PR610, a hypoxia-activated, irreversible multikinase inhibitor aimed at treating cancer...The first clinical study, to be conducted in the U.S...Protalex Inc., of Summit, N.J., said data from its Phase Ib dose-escalation trial showed that PRTX-100 was well tolerated at all dose levels in adult patients with rheumatoid arthritis (RA) and, at the higher doses, more patients showed

If approved, the product, indicated for the treatment of autoimmune and inflammatory diseases, will enter clinical trials...LX7101 was well tolerated at all doses evaluated, and statistically significant improvements in measures of intraocular pressure were observed at both dose levels, compared to vehicle...Medivation Inc., of San Francisco, and Astellas Pharma Inc., of Tokyo, published Phase III results from the AFFIRM trial of enzalutamide (MDV3100) in metastatic castration-resistant prostate

Antisense Pharma GmbH, of Regensburg, Germany presented complete data from its Phase I/II study of trabedersen, an antisense compound that specifically inhibits expression of transforming growth factor beta 2 (TGF-β2) – a protein which is overexpressed in advanced tumors – in patients with advanced pancreatic cancer, malignant melanoma or colorectal cancer...CytRx Corp., of Los Angeles, reported Phase Ib/II data showing that tumor-targeting doxorubicin conjugate INNO-206 produced a clinical benefit

The company said the compound was well tolerated at all dose levels, and it will consider out-licensing opportunities...ImmunoCellular Therapeutics Ltd., of Woodland Hills, Calif., will present new data from its previously completed Phase I trial of ICT-107 in glioblastomoa multiforme at the American Society of Clinical Oncology meeting in Chicago

The trial will enroll approximately 300 patients and will evaluate Arikace 560 mg, once-daily, delivered via an eFlow Nebulizer System by PARI Pharma GmbH compared to TOBI (inhaled tobramycin solution...It will enroll up to 160 patients at clinical centers in the U.S...The study enrolled 15 patients with midstage Parkinson's who were experiencing reduced benefit on L-dopa equivalent therapy, and randomized them to three ascending dose levels

The project, "Human genetics-driven discovery of memory-modulating drugs," will start in March and will include three clinical studies supported by a CTI grant for three years...Niiki Pharma Inc., of Hoboken, N.J., said it completed the dose-escalation portion of its Phase I trial of NKP-1339, a small molecule designed to down-regulate GRP78, a tumor survival and anti-apoptosis factor...The study will involve about 32 subjects who currently are not undergoing vaso-occlusive crisis and will comprise

AMAG Pharmaceuticals Inc., of Lexington, Mass., presented new clinical data for Feraheme (ferumoxytol), which is approved for iron deficiency anemia in chronic kidney disease...Clavis Pharma ASA, of Oslo, Norway, reported interim efficacy data from a Phase II trial showing that elacytarabine in combination with idarubicin produced a complete remission rate in about 46 percent (12 of 26) of patients with early stage acute myeloid leukemia who had failed cytarabine-containing first-course

Bionomics Ltd., of Adelaide, Australia, said the higher dose level of 16 mg/m2 was cleared for BNC105, a vascular-disrupting agent that is being tested in a clinical trial in combination with mTOR inhibitor Afinitor (everolimus, Novartis AG) in patients with metastatic renal cell cancer...Niiki Pharma Inc., of Hoboken, N.J., reported interim data from a Phase I study of NKP-1339 in patients with metastatic solid tumors resistant to standard therapies showing that six of the first 24 patients

Acceleron Pharma Inc., of Cambridge, Mass., said it started a Phase I study of ACE-536, a ligand trap designed to increase red blood cells and hemoglobin by inhibiting member of the TGF-beta superfamily involved in late stages of erythropoiesis...Under the firms' 2010 deal, Otsuka will contract with Acucela for early clinical development in exchange for an opt-in right to co-develop and co-promote the compound in the U.S...Ascendis Pharma A/S, of Copenhagen, Denmark, said a Phase II study of ACP-001

Acacia Pharma Ltd., of Cambridge, UK, started a Phase II study of APD515, an oromucosal formulation of a currently marketed drug, in xerostomia (dry mouth) in advanced cancer patients...The total number of patients to be enrolled will depend on how many ascending dose levels are needed to reach the maximum-tolerated dose...Threshold Pharmaceuticals Inc., of Redwood City, Calif., initiated a clinical trial of TH-302 in combination with bevacizumab (Avastin, Roche AG) in patients with recurrent high

Endotis Pharma, of Paris, enrolled the first patients in a Phase IIa trial of anticoagulant EP217609 and its specific antidote, avidin, to manage coagulation during open-heart surgery...Oxford BioMedica plc, of Oxford, UK, said the first dose level of RetinoStat was safe and well tolerated at one month following treatment

The single-dose level study is designed to recruit two patient groups: one with up to 37 CML patients and the other up to 37 AML patients...Verona Pharma plc, of London, applied to the Medicines and Healthcare Products Regulatory Agency for permission to carry out a clinical trial of its investigational therapy, RPL554, for asthma, allergic rhinitis and chronic obstructive pulmonary disease (COPD

Endotis Pharma, of Paris, said it has successfully completed a Phase I study assessing in healthy subjects the neutralization of the anticoagulant EP217609 by its specific antidote avidin...The firm said administration of the third-dose level in patients recruited since September was completed as expected...RFS Pharma LLC, of Atlanta, said the company was selected by the U.S. Departments of Treasury and Health and Human Services to receive $244,479 in tax credits under the Qualifying Therapeutic